David Matly

David Matly is the Executive Vice President, Chief Commercial and Business Development Officer at Inhibrx, Inc., a biotechnology company.1 He brings extensive experience in commercial launch and leadership across both orphan diseases and oncology.3

Professional Background

Novartis Experience: Prior to joining Inhibrx, Matly held significant roles at Novartis:

• Global Vice President of the MDS/AML franchise
• Global commercial lead for the sickle cell disease therapeutic area
• Global commercial lead for PROMACTA/REVOLADE

During his time at Novartis, he was responsible for launch preparations, portfolio building, and evaluating in-licensing and M&A opportunities.1

Earlier Career: Before Novartis, Matly served as:

• VP of Business Development at Chrono Therapeutics
• Various positions of increasing responsibility at Eli Lilly, including leading the US launch of CYRAMZA in metastatic lung cancer1

Current Role at Inhibrx

At Inhibrx, Matly is responsible for:

• Commercial operations
• Medical affairs
• Market access
• Business development functions1

Education

Matly holds the following degrees:

• B.S. in Industrial Engineering from Purdue University
• M.B.A. from Harvard Business School12

Recent Developments

In January 2024, Matly shared news about Inhibrx entering into a definitive agreement with Sanofi to acquire their INBRX-101 program, demonstrating his involvement in significant business developments for the company.4

David Matly is based in San Diego, California, and has over 500 connections on LinkedIn.25